Childhood cancer

All families in Sweden with a child who is diagnosed with cancer will be offered to participate in a special project within Genomic Medicine Sweden, which is financed by the Swedish Childhood Cancer Fund. This project will increase knowledge on why childhood cancer occurs and improve possibilities for making a faster and more detailed diagnosis. The analyses may also enable the ability to detect targets for treatment at an early stage.

A little boy wearing boxing gloves stands next to a drip stand

Roughly 300 children are diagnosed with cancer each year in Sweden. Today diagnostics, care and treatment of children with cancer are already well coordinated on a national level. We are now working to enable routine analysis of all genes, so called whole genome sequencing, for all types of childhood cancer. We will also develop tools to analyse and clinically interpret the genomic data that results from these analyses. In addition to whole genome sequencing, other supplementary sequencing techniques will be used. One important challenge is to perform these analyses quickly enough for the information to benefit individual children. In the long run, results from the project will also provide important knowledge about how similar analyses can be implemented for more common cancers affecting adults. 

This investment in childhood cancer is funded by the Swedish Childhood Cancer Fund (Barncancerfonden) and is conducted in collaboration with the Swedish Childhood Tumour Biobank (Barntumörbanken), the Nordic Childhood Leukemia Biobank (Nordiska barnleukemibiobanken), and the Swedish healthcare system.

Introduction disease areas

Genomic Medicine Sweden (GMS) focuses primarily on disease areas where there is currently definite evidence that suggests that genetic analyses can be used to diagnose disease, or where genetic deviations are important to prognostic assessment, choice of treatment and follow-up. We work primarily with rare diseases, solid tumours, hematological malignancies, infectious diseases and pharmacogenomics. GMS also has a particular focus on childhood cancer.